Search for IHHT and you will quickly run into critical voices: not enough large trials, overblown advertising, steep prices. That criticism is fair — and for us it is not a problem but the better starting point for a conversation. Knowing where a method ends lets you make a deliberate decision instead of a hopeful one.
This article works through the four most common objections in turn: the evidence, the marketing language around the phrase "cell training", the cost, and the quality gap between providers. We won't argue away anything that is true. We'll put it in context.
1. "The large trials are missing" — true
The core objection is correct: there are still no large, standardised long-term trials of IHHT with thousands of participants. The 2022 systematic review gathered the available human studies and arrives at exactly that picture — signals in performance and health-related outcomes, but small groups, widely differing protocols and inconsistent outcome measures [1].
What often gets lost in the criticism: "limited evidence" is not the same as "disproven". Controlled work does exist. One controlled study in patients with coronary artery disease compared a course of IHHT against a control group and described changes in exercise-tolerance measures [3]. Findings like these are research results, not proof of benefit in your individual case — but they show the field is being worked on seriously and methodically.
- Established: the cellular oxygen sensor exists and is well described [4].
- Under study: individual protocols in exercise tolerance, sleep and cognition [1][3].
- Open: the optimal dose, long-term effects and who responds particularly well.
A young research field is not proof — but it isn't disproof either. The honest sentence is: we know some things, and plenty we don't.
2. "The results contradict each other" — and why
It's true that findings diverge. The main reason is rarely that the principle fails, but that "IHHT" doesn't describe one single procedure. Simulated altitude, interval length, number of cycles, sessions per week, total length of the course — all of this varies substantially between studies.
Research on intermittent hypoxia made the point early: it is a matter of dose [2]. Mild, short, monitored stimuli are assessed very differently in the literature than strong or unmonitored drops in oxygen. Lining up trials with different doses and calling the result "contradictory" effectively compares different procedures.
For anyone considering it, that is the single most useful insight here. The question isn't "does IHHT work?" but "which protocol, how often, and with what supervision?"
3. "Long COVID, ME/CFS, burnout" — restraint is mandatory
For serious chronic conditions the criticism is most clearly justified, and we agree with it. There are practice reports and small pilot studies, but no broad proof of efficacy. That is why ZELLGIPFEL holds a clear line: we do not suggest improvement, relief or cure for any condition. Doing so would be neither credible nor lawful.
If you have a diagnosis or are having symptoms investigated, the decision about IHHT belongs with your doctor — before the first session, not after it. That is not a formality; it is precisely where credible providers separate from careless ones.
4. "Cell training is marketing" — what the phrase actually means
The objection targets a particular story: that oxygen restriction "destroys old, damaged power plants" and replaces them with new ones. In that sweeping form it is not established for breathing through a mask, and the critics are right. Cellular remodelling is described in basic research, but jumping from cell culture to a person in a 35-minute session is not supported.
The same applies to the 2019 Nobel Prize. It was awarded for the discovery of how cells sense oxygen and respond with a genetic programme [4]. That is the biological background that makes IHHT plausible in the first place — and no more than that. The prize does not prove that a given device improves given symptoms. Selling it as evidence of efficacy stretches it too far.
So we use "cell training" descriptively: as an image for a short, measured stimulus the body receives at rest. Not as a promise of effect.
5. "Over a thousand euros per course" — do the maths first
Also true: a course usually runs to 10 to 15 sessions, and single sessions often cost between 80 and 150 euros. German statutory health insurance does not cover it; private insurers reimburse only in individual cases. It is a self-pay service, and nobody should gloss over that.
What we took from this criticism: cost belongs before the decision, not in the invoice afterwards. So we put the total cost of a course on the table before anything starts, and work through the alternatives honestly — on-site sessions, your own device or a rental can differ considerably depending on your goal and timeframe. If you only want to try two or three sessions, we won't sell you a course.
- Know upfront: number of sessions, total price, possible extension.
- Compare: on-site sessions versus renting or buying across several months.
- Stay realistic: don't budget for statutory insurance reimbursement.
- Be free to stop: a course is not a subscription without an exit.
6. "No standards" — how to spot a credible provider
The wide spread of devices and protocols is a genuine quality problem in this market. Which is why the most important thing to check isn't the method but the provider. In the EU, these devices fall under the Medical Device Regulation [5] — a verifiable minimum you are entitled to ask about, and should.
- A certified medical device rather than an unverified wellness gadget.
- A thorough intake conversation covering contraindications and stopping criteria.
- Continuous monitoring of oxygen saturation and pulse, not just a fixed programme.
- A person you can reach during the session.
- Written documentation of your readings across the whole course.
- No health claims — neither spoken nor in advertising.
The best answer to missing standards is transparency: traceable technology, documented readings, and a provider who also says what they don't know.
7. "Not everyone feels anything" — correct, and we plan for it
People respond differently. Some report better sleep or more capacity in daily life after a course; others notice nothing. With an individually dosed stimulus that is to be expected, and the literature describes it too [1].
In practice: decide in advance what you will judge the difference by — sleep quality, recovery after exertion, focus in the afternoon. Keep it simple and write it down. After a handful of sessions you'll see whether anything is moving in your direction. If it isn't, that is a legitimate result and a good reason to stop.
What's left once you take the criticism seriously
What remains is a method carried out at rest, dosed individually, with a research base that is promising but not settled. That is less than some advertising claims — and more than blanket dismissal suggests.
So our recommendation is unspectacular: talk to your doctor before you start, especially with existing heart, circulatory or lung conditions, during pregnancy, or with an acute infection. Have the technology, the protocol and the total cost explained to you. Then decide, without pressure, whether you want to try it.
If you'd like to go through those questions with someone who will also advise against a course when it doesn't fit — that's exactly what our intake conversation is for.